Glycation Stress-Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer.
Oier Azurmendi Senar, Kosta Stosic, Christelle Bouchart, Julie Navez, Jawad Tarfouss, Rebekah Crake, Laurine Verset, Pieter Demetter, Marjorie Mauduit, Thierry Conroy, Jerome F. Cros, Rémy Nicolle, Manuel Saiselet, Joel Rodrigues Vitória, Vincent Detours, , Jean-Luc Van-Laethem
The paper develops a 16-gene signature (MG-GEM) that predicts survival benefit from adjuvant gemcitabine in resectable pancreatic cancer based on glycation stress, outperforming existing signatures.
bioRxiv · Jul 7, 2025 · PreprintCancer Biology